Dr. Reddy’s Laboratories Ltd., incorporated in the year 1984, is a Large Cap company (having a market cap of Rs 79544.46 Crore) operating in Pharmaceuticals sector.
Dr. Reddy’s Laboratories Ltd. key Products/Revenue Segments include Pharmaceuticals, Licence Fees, Other Operating Revenue, Spent Chemicals, Service Income and Scrap for the year ending 31-Mar-2021.
Financials
For the quarter ended 30-09-2021, the company reported a Consolidated Total Income of Rs 5992.40 Crore, up 18.59 % from last quarter Total Income of Rs 5053.00 Crore and up 20.76 % from last year same quarter Total Income of Rs 4962.10 Crore. Company reported net profit after tax of Rs 971.10 Crore in latest quarter.
Investment Rationale
The stock is trading at an attractive valuation of 21x 1-year forward P/E vs. the historical average of 25x. The brokerage values the stock using the SOTP valuation, which implies a 22x P/E on Dec’23E EPS, Revlimid NPV of Rs200/share and vaccine NPV of Rs140/share.
Promoter/FII Holdings
Promoters held 26.72 per cent stake in the company as of 30-Sep-2021, while FIIs owned 27.76 per cent, DIIs 21.4 per cent.
(Disclaimer: Recommendations given in this section or any reports attached herein are authored by an external party. Views expressed are that of the respective authors/entities. These do not represent the views of Economic Times (ET). ET does not guarantee, vouch for, endorse any of its contents and hereby disclaims all warranties, express or implied, relating to the same. Please consult your financial adviser and seek independent advice.
